The global Hereditary Angioedema (HAE) market is witnessing substantial growth as awareness regarding rare genetic disorders continues to rise worldwide. HAE is a rare but potentially life-threatening condition characterized by recurrent swelling episodes in different body parts, including the airway, abdomen, and extremities. Increasing diagnosis rates, improved access to specialized therapies, and strong pharmaceutical investments are contributing to the expansion of the market. According to industry analysis, Hereditary Angioedema market size is expected to reach US$ 7.38 Billion by 2034 from US$ 3.88 Billion in 2025. The market is anticipated to register a CAGR of 7.41% during the forecast period 2026–2034.

The rising demand for targeted biologics and prophylactic therapies is significantly boosting the Hereditary Angioedema Market Share across major healthcare economies. Pharmaceutical companies are increasingly focusing on novel kallikrein inhibitors, monoclonal antibodies, and oral therapies that improve patient convenience and long-term disease management. North America currently dominates the global market owing to advanced healthcare infrastructure, favorable reimbursement systems, and higher awareness among physicians and patients. Europe is also witnessing strong adoption of innovative therapies, while Asia-Pacific is expected to emerge as a high-growth region due to improving healthcare access and growing investments in rare disease treatment.

Get Sample PDF @ https://www.theinsightpartners.com/sample/TIPRE00005410

Rising Prevalence of Rare Genetic Disorders Supporting Market Expansion

The increasing prevalence of hereditary angioedema and improved genetic screening programs are key factors driving market growth. HAE affects approximately 1 in 10,000 to 1 in 50,000 people globally, and many cases remain undiagnosed due to symptom overlap with other conditions. Governments and healthcare organizations are emphasizing early diagnosis initiatives, which is leading to greater treatment adoption. Additionally, patient advocacy groups are actively conducting awareness campaigns to educate healthcare professionals and patients about the condition.

The market is also benefiting from advancements in precision medicine and biologic drug development. New therapies targeting the kallikrein-bradykinin pathway are demonstrating improved efficacy and reduced attack frequency among patients. These innovations are transforming HAE management from emergency treatment toward preventive care, creating significant commercial opportunities for market players.

Growing Adoption of Prophylactic Therapies

Preventive therapies are gaining strong momentum within the hereditary angioedema treatment landscape. Patients and healthcare providers are increasingly preferring long-term prophylactic treatments to minimize the occurrence and severity of attacks. Subcutaneous and oral formulations are becoming particularly popular because they offer easier administration compared to intravenous therapies.

The demand for self-administration therapies is also increasing as patients seek convenient home-based treatment options. Pharmaceutical companies are focusing on developing next-generation oral drugs and gene-based therapies that can deliver sustained symptom control. These innovations are expected to reshape the competitive dynamics of the market during the forecast period.

North America Maintains Dominant Market Position

North America continues to account for the largest revenue contribution in the hereditary angioedema market. The region benefits from the presence of leading biotechnology companies, high healthcare expenditure, and strong regulatory support for orphan drugs. The United States remains the key contributor due to increasing patient awareness, favorable reimbursement frameworks, and rapid approval of innovative therapies.

Europe follows closely behind, supported by expanding research initiatives and rare disease treatment programs. Meanwhile, Asia-Pacific is projected to register the fastest growth over the coming years due to improving diagnostic capabilities and rising healthcare investments in countries such as China, India, and Japan.

Pipeline Innovations Creating Future Opportunities

Ongoing research and development activities are expected to create significant opportunities for the hereditary angioedema market. Several pharmaceutical and biotechnology firms are investing in advanced pipeline therapies, including RNA-based therapeutics, monoclonal antibodies, and gene-editing technologies.

The growing focus on personalized medicine is likely to improve treatment outcomes and reduce healthcare burdens associated with emergency hospitalizations. In addition, collaborations between pharmaceutical companies and research institutes are accelerating the pace of innovation within the rare disease segment. These developments are anticipated to strengthen market competitiveness and improve patient quality of life over the next decade.

Key Players Operating in the Hereditary Angioedema Market

• BIOCRYST PHARMACEUTICALS, INC
• CSL
• Ionis Pharmaceuticals, Inc.
• Merck Sharp & Dohme Corp
• Pharming Group N.V.
• Sanofi N.V.
• Shire plc.
• Teva Pharmaceutical Industries, Ltd.
• Attune Pharmaceuticals
• KalVista Pharmaceuticals, Inc

Future Outlook of the Hereditary Angioedema Market

The future outlook for the hereditary angioedema market remains highly positive due to increasing investments in rare disease therapeutics and the growing adoption of innovative treatment options. The market is expected to witness continuous advancements in targeted therapies, improved diagnostic technologies, and patient-centric treatment approaches.

Related Report:

1) Microcarriers Market Key Players and Opportunities by 2030

2) Generic Drugs Market Report 2031 by Segments, Geography, Dynamics

3) Empty Capsules Market Demand, Trends & Forecast to 2031

About Us -

The Insight Partners provides comprehensive syndicated and tailored market research services in the healthcare, technology, and industrial domains. Renowned for delivering strategic intelligence and practical insights, the firm empowers businesses to remain competitive in ever-evolving global markets.

Contact Us:
Ankit Mathur | The Insight Partners
E-mail: ankit.mathur@theinsightpartners.com
Phone: +1-646-491-9876

Also Available in : Korean German Japanese French Chinese Italian Spanish